Catalyst Pharmaceutical Partners Announces Fourth Quarter and Year-End 2013 Financial Results and Provides Corporate Update

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/12/2026

1. ADBE
2. SPCX
3. USO
4. SPY
5. RH
6. NVDA
7. RKLB
8. CRM
9. MSFT
10. CRWV

Go back to Catalyst Pharmaceutical Partners Announces Fourth Quarter and Year-End 2013 Financial Results and Provides Corporate Update

Aegis Still Positive on Catalyst (CPRX) Following Q4 Results; Credit for Firdapse Still Not Given

March 19, 2014 11:20 AM EDT

Aegis Capital reaffrms its Buy rating and $6 price target on Catalyst Pharmaceutical Partners Inc. (Nasdaq: CPRX) following Q4 results and update issued earlier today.

NOTE: Catyalyst reported Q4 loss of $0.05 per share, versus the analyst loss estimate of $0.07 per share. CEO Patrick J. McEnany commented, Catalyst made significant progress... More